Abstract

Bleeding disorders and haemorrhage cause considerable morbidity and mortality in the industrialized world, as shown by the more than 2 million patients who received treatment for serious blood loss in 2002. Historically, these disorders have been treated with products derived from human plasma or animal sources. With the advent of recombinant technologies, new products have been developed that are generally perceived as safer and which have well-defined specificity of action and potency. Recombinant biologics have also provided some unforeseen benefits, yielding new insights into the mechanism of haemostasis as well as novel pharmacological strategies.

Author affiliations

1. ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, Washington 98102, USA.
   Email: bishopp@zgi.com
2. Jeff Lawson, Duke University Medical Center, Durham, North Carolina 27708, USA.
   Email: lawso717@acpub.duke.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.